ABBV vs LLY: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Eli Lilly and Company — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-01.
AbbVie Inc. · Healthcare
$197.69
+6.3% upside to fair value
Grade C
High Quality
VS
Eli Lilly and Company · Healthcare
$934.34
+17.6% upside to fair value
Grade B
High Quality
QuantHub Verdict
LLY has more upside to fair value
(+17.6%).
LLY trades at a lower forward P/E
(33.1x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
LLY |
| Current Price |
$197.69 |
$934.34 |
| Fair Value Estimate |
$210.22 |
$1,098.43 |
| Upside to Fair Value |
+6.3%
|
+17.6%
|
| Market Cap |
$349.7B |
$882.8B |
| Forward P/E |
83.3x
|
33.1x
|
| EV / EBITDA |
23.4x
|
27.9x
|
| Price / Sales |
5.7x
|
12.2x
|
| Price / FCF |
18.7x
|
65.0x
|
| Revenue Growth YoY |
+10.0%
|
+55.5%
|
| Gross Margin |
70.2%
|
82.7%
|
| Operating Margin |
26.7%
|
46.3%
|
| Return on Equity |
-361.6%
|
101.3%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
5.35%
|
1.54%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology, neuroscience, oncology, and aesthetics. The company benefits from a durable competitive moat driven by blockbuster drugs such as Skyrizi and Rinvoq, which are experiencing rapid growth and offsetting declines from Humira due to biosimilar competition. Despite a high trailing and forwa…
Eli Lilly and Company is a leading global pharmaceutical firm with a dominant position in the diabetes and obesity markets, driven by its blockbuster GLP-1 drugs Mounjaro and Zepbound which generated $36.5 billion in FY2025. The company reported $65.2 billion in total revenue for 2025, making it the top pharma by revenue globally. It exhibits high business quality with a durable competitive moat …
Accumulation Zones
| Metric |
ABBV |
LLY |
| Zone Low |
$157.66 |
$823.82 |
| Zone High |
$178.69 |
$933.67 |
| In Buy Zone? |
No
|
No
|